Did couple cycles but the last one leaved me with no libido.
What can I do? undefined length until some libido is back, and hcg. Its really hard to get a hard on watching porn.. and I force myself, there is not really libido. I am afraid Ill have to dump my new gf because my dick doesnt work.
I have and appointment with an Endo but its until next year..why my libido didn't come back even injecting test. I feel really fucked up
You really stressed this point a lot, and it's clearly weighting heavy on you.. If your concerned about libido and you wish to TREAT THE SYMPTOMS until you see your endo and get blood work, like I suggested prior, proviron may perhaps assist with your situation, and within realm of possibility it may restore your libido until you speak with your endo and heed his suggestions and anything else under his care. If your looking to treat libido symptoms this is merely a suggestion!
Either way, Good luck!
on an other note:
To clear some confusion here, some studies have made mention that there was not normally any suppression with gonadotrohins or endogenous test production, it's been cited that later studies found SOME suppressive properties at dosages ranging from 100-150,however these individuals possessed higher FSH and LH levels,above normal..People with NORMAL or low levels were impervious at these above therapeutic dosages..(In theory wouldn't the elevated levels now return to a normal base,no where does any study cite HTPA suppression,just lowering of ELEVATED levels above norm..One studies indicated 300-450mgs daily shown to decrease test plasma levels in some users.. (I doubt anyone here is going to use that much for 6 weeks or more).. IMO & findings, I don't see any evidence stated anywhere in any medical journal that exists to my knowledge that indicates Proviron is suppressive by nature on a moderate therapeutic dosage that will hinder HTPA recovery,if anything is shows more studies citing LH stimulation.. interesting stuff nonetheless!
I don't believe there will ever be a definitive answer to this topic!
The effect of mesterolone on sperm count, on serum follicle stimulating hormone, luteinizing hormone, plasma testosterone and outcome in idiopathic oligospermic men.
Two hundred fifty subfertile men with idiopathic oligospermia (count less than 20 million/ml) were treated with mesterolone (100-150 mg/day) for 12 months. Seminal analysis were assayed 3 times and serum follicle stimulating hormone (FSH) luteinizing hormone (LH) and plasma testosterone were assayed once before treatment and repeated at 3, 6, 9 and 12 months after the initiation of treatment. One hundred ten patients (44%) had normal serum FSH, LH and plasma testosterone, 85 patients (34%) had low serum FSH, LH and low plasma testosterone. One hundred seventy-five patients (70%) had moderate oligospermia (count 5 to less than 20 million/ml) and 75 patients (30%) had severe oligospermia (count less than 5 million/ml). Seventy-five moderately oligospermic patients showed significant improvement in the sperm density, total sperm count and motility following mesterolone therapy whereas only 12% showed improvement in the severe oligospermic group. Mesterolone had no depressing effect on low or normal serum FSH and LH levels but had depressing effect on 25% if the levels were elevated. There was no significant adverse effect on testosterone levels or on liver function. One hundred fifteen (46%) pregnancies resulted following the treatment, 9 of 115 (7.8%) aborted and 2 (1.7%) had ectopic pregnancy. Mesterolone was found to be more useful in patients with a sperm count ranging between 5 and 20 million/ml. Those with severe oligospermia (count less than 5 million) do not seem to benefit from this therapy.
------------------------------------------------------------
The hormone response to a synthetic androgen (mesterolone) in oligospermia.
Forty subfertile men with oligospermia were treated with a synthetic androgen (Mesterolone). The effect of the drug was evaluated by measuring serum testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH) and analysing the semen before and after treatment. The results demonstrated that in twenty-three patients treated for 6-9 months there was a significant decrease in serum testosterone (P less than 0.01); the means +/- SEM before and after treatment were 17.05 +/- 0.95 and 14.7 +/- 0.95 (nmol/l serum) respectively. There was a pronounced increase in serum LH (P less than 0.01), the values being 2.73 +/- 0.26 and 3.61 +/- 0.3 (u/l) respectively. However, no significant difference was found in serum FSH before and after treatment. The sperm concentration showed a variable response to treatment. In twenty-one patients there was either no change or worsening in the sperm concentration, whereas in nineteen patients an improvement was observed. The analysis of variance of sperm concentration and motility for the periods before and after treatment, for all the patients, showed no significant difference in the sperm concentration F1.145 = 2.82 (P=0.1).
-----------------------------
PRESCRIBING INFORMATION
PROVIRON
Tablets
COMPOSITION
Each tablet contains 25 mg mesterolone.
ACTION
-dihydro-testosterone, which is ***945;-methyl compound of 5***945;Mesterolone is the 1
considered to be the proper active androgen in many androgen-dependent target
organs.
Proviron is an oral androgen preparation which has only a slight central inhibitory
effect and, consequently,
no restrictive effect on testicular function.
Proviron balances a deficiency of androgen formation which begins to fall gradually
with increasing age. Therefore,
Proviron is suitable for the treatment of all conditions
caused by deficient endogenous androgen formation.
In the recommended therapeutic
dosage, Proviron will not impair spermatogenesis. Proviron is especially well
tolerated by the liver.
PHARMACOKINETICS AND METABOLISM
Following oral ingestion mesterolome is rapidly and almost completely absorbed in a
wide dose range of 10 - 100 mg. The intake of Proviron generates maximum serum
drug levels of 3.1 ± 1.1 mg/ml after 1.6 ± 0.2 hours. Thereafter drug levels in serum
decrease with a terminal half-life of 12 13 hours. Mestorelone is bound to serum
proteins by 98%. Binding to albumin accounts for 40% and binding to SHBG to 58%.
Mestorelone is rapidly inactivated by metabolism. The ********* clearance rate from
serum accounts for 4.4 ± 1.6 ml. min ***8722;1.kg***8722;1 .
There is no renal excretion of unchanged drug. The main metabolite has been
identified as 1***945; - methyl-androsterone, which - in conjugated form - accounts for 55 -
70% of renally excreted metabolites. The ratio of main metabolite glucoronide to
sulphate was about 12:1. As a further metabolite 1***945; - methyl- 5***945; androstane-3***945;, 17***946;-
diol has been recognized, which accounted for about 3% of renally eliminated
metabolites. No ********* conversion into estrogens or corticoids has been observed.
In form of metabolites mesterolone is excreted by about 85% of dose with the urine
and by about 14% of dose with the faeces. Within 7 days 93% of dose have been
recovered in excreta, the half of which had been excreted within 24 hours.
The absolute bioavailability of mesterolone was determined to about 3% of the oral
dose.
The daily intake of Proviron will lead to an about 30% increase in drug serum levels.
INDICATIONS
Androgen therapy in male patients only.
Reduced efficiency in middle and advanced age •
Complaints attributable to androgen-deficiency, such as reduced efficiency,
easy fatigability, lack of concentration, weak memory, disturbances of libido and
potency, irritability, disturbances of sleep, depressive moods, and general vegetative
complaints, can be overcome or improved by the use of Proviron tablets.
Potency disturbances
•Potency disorders based on an androgen deficiency are eliminated by
administration of Proviron. If other factors are the sole cause or if they contribute to
the disorders, Proviron may be administered in support of other therapeutic measures.
Hypogonadism
•Growth, development and function of androgen-dependent target organs are
stimulated by Proviron.
It promotes development of secondary male sex
characteristics in cases of prepuberal androgen-deficiency.
Proviron eliminates deficiency symptoms in cases where a loss of gonadal
function has occurred postpuberally.
Infertility
•Oligozoospermia and deficient Leydig-cell secretion may be the cause of
infertility. With Proviron, sperm count and sperm quality as well as the fructose
concentration in the ejaculate can be improved or normalized, thus increasing the
chances of procreation
